Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis

Current Medical Research and Opinion

Volumn 24, Issue 1, 2008, Pages 287-296

  White, Eric M ^a   Macy, Jonathan I ^b   Bateman, Kirk M ^c   Comstock, Timothy L ^c,d  

^a Complete Family Vision Care ^*  (United States)

^b Macy Eye Center   (United States)

^c BAUSCH AND LOMB   (United States)

^d Bausch and Lomb   (United States)

Author keywords

Blepharokeratoconjunctivitis; Dexamethasone; IOP; Loteprednol etabonate; Ocular inflammation; Tobramycin

Indexed keywords

DEXAMETHASONE PLUS TOBRAMYCIN; LOTEPREDNOL ETABONATE PLUS TOBRAMYCIN;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ANXIETY; ARTICLE; BLEPHAROKERATOCONJUNCTIVITIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EPICONDYLITIS; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; FEMALE; FOREIGN BODY; HEADACHE; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BLEPHARITIS; DEXAMETHASONE; DRUG COMBINATIONS; FEMALE; HUMANS; INTRAOCULAR PRESSURE; KERATOCONJUNCTIVITIS; MALE; MIDDLE AGED; TOBRAMYCIN; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 38749147307     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X253898     Document Type: Article

References (22)

1. McCulley JP. Blepharoconjunctivitis. Int Ophthalmol Clin 1984;24:65-77
2. Leibowitz HM. The red eye. New Engl J Med 2000;343:345-51
3. Doan S, Gabison EE, Nghiem-Buffet S, et al. Long-term visual outcome of childhood blepharokeratoconjunctivitis. Am J Ophthalmol 2007;143:528-9
4. Hammersmith KM, Cohen EJ, Blake TD, et al. Blepharokeratoconjunctivitis in children. Arch Opthalmol 2005,123:1667-70
5. Viswalingam M, Rauz S, Morlet N, Dart JK. Blepharokeratoconjunctivitis in children: diagnosis and treatment. Br J Ophthalmol 2005;89:400-3
6. Zylet® Prescribing Information, 2005, Bausch & Lomb Pharmaceuticals, Inc.: Tampa (FL), USA
7. TobraDex® Prescribing Information, 2005, Alcon Pharmaceuticals/ Laboratories, Inc.: Fort Worth (TX), USA
8. Rhee SS, Mah FS. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharokeratoconjunctivitis. Adv Ther 2007;24:60-7
9. ICH harmonised tripartite guideline E6: guideline for good clinical practice. London, England: ICH; 2002. Available at: http://www.emea.europa.eu/ pdfs/human/ich/013595en.pdf [last accessed September 14, 2007]
10. Declaration of Helsinki: ethical principles for medical research involving human subjects. Ferney-Vottaire, France: World Medical Association; 1964. Available at: http://www.wma.net/e/ethicsunit/helsinki.htm [last accessed September 14, 2007]
11. Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993;12:313-21
12. Dell SJ, Shulman DG, Lowry GM, Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis [Loteprednol Allergic Conjunctivitis Study Group]. Am J Ophthalmol 1997;123:791-7
13. Loteprednol Etabonate Postoperative Inflammation Study Group 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmology 1998;105:1780-6
14. Farpour B, McClellan KA. Diagnosis and management of chronic blepharokeratoconjunctivitis in children. J Pediatr Ophthalmol Strabismus 2001;38:207-12
15. Stewart RH, Smith JP, Rosenthal AL. Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate. Curr Eye Res 1984;3:198-205
16. Holland EJ, Bartlett JD, Paterno MR, et al. The effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008;27 [doi:10.1097/ICO.0b013e31815873c7]
17. Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993;9:157-65
18. Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 1998;7:266-9
19. Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three level response. Invest Ophthalmol 1963;4:187-97
20. Becker B. Intraocular pressure response to topical steroids. Invest Ophthalmol 1965;4:198-205
21. Kwok AK, Lam DS, Ng JS, et al. Ocular-hypertensive response to topical steroids in children. Ophthalmology 1997;104:2112-6
22. Lam DS, Fan DS, Ng JS, et al. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Experiment Ophthalmol 2005;33(3):252-8